Atlas Trials

A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients

Clinical trial NCT06497985 · RECRUITING

Trial details

NCT number
NCT06497985
Sponsor
Chipscreen Biosciences, Ltd.
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Colorectal Cancer
Start date
2024-12-06
Primary completion
2028-05-31
Enrollment
430

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.